menu
    • menu

    Company profile for Lonza Group

    lebsa-m-2024-10-21

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lonza is one of the world's leading and most-trusted suppliers to the Pharma&Biotech and Specialty Ingredient markets. We harness science and technology to create products that make people's and animals' lives healthier and that enhance the overall quality of life and well-being. Our products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preserva...
    Lonza is one of the world's leading and most-trusted suppliers to the Pharma&Biotech and Specialty Ingredient markets. We harness science and technology to create products that make people's and animals' lives healthier and that enhance the overall quality of life and well-being. Our products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lonza GroupSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Muenchensteinerstrasse 38 CH-4002 Basel
    Telephone
    Telephone
    +41 61 316 81 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lonza.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lonza
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/LonzaGroup?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We have built considerable expertise in GLP-1 drug development through our oral peptide programs”

    “We have built considerable expertise in GLP-1 drug development through our oral peptide programs”

    This week, Speak Pharma interviews Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, a drug development and manufacturing accelerator that offers a range of integrated programs and tailored services to over 550 customers. Lewis discusses the latest developments in the delivery of oral peptides and how Quotient Sciences is helping customers overcome drug development challenges in this exciting space. 🔑HIGHLIGHTS// latest developments in the delivery of oral peptides Why have glucagon-like peptide-1 (GLP-1) therapies become essential for treating type 2 diabetes and obesity? What makes the oral delivery of peptides such as GLP-1 challenging? GLP-1 and gastric inhibitory polypeptide (GIP) are essential incretin hormones involved in regulating glucose metabolism. Both are produced in the gastrointestinal (GI) tract in response to food intake, specifically glucose and fats. GLP-1 enhances insulin secretion from the pancreas, but only in response to elevated blood glucose levels. GIP has overlapping effects that are slightly contradictory – it promotes the production of glucagon, which can counteract its glucose-lowering effects. In people with type 2 diabetes, the body’s response to incretin hormones is impaired. However, the GLP-1 pathway remains relatively intact, allowing it to still stimulate insulin production. There is a more significant impairment for GIP, making it not as effective. This makes GLP-1 a more attractive target for treatment, leading to the development of several GLP-1 receptor agonists for managing type 2 diabetes, obesity, and potentially other conditions. Incretin analogs, like GLP-1 agonists, have traditionally been challenging to deliver orally. As a result, these medications are most often given by injection. But we know that patients generally prefer taking a tablet or capsule treatment rather than an injection. Peptides such as GLP-1 analogs go through a challenging journey before being absorbed. This is because the gastrointestinal tract functions to digest these into either small amino acids or very short pieces of polypeptides. Even if they get to the epithelium, they tend to have poor permeability, usually resulting in less than 1 percent bioavailability (the proportion of a drug that enters the circulatory system when introduced into the body, thereby having an active effect). Various technologies have been developed to overcome bioavailability issues, with permeation enhancers being the most advanced and validated. For example, SNAC is the permeation enhancer used in Novo Nordisk’s oral pill Rybelsus to promote semaglutide absorption. Mycapssa (octreotide capsules), marketed by Chiesi, employs the Transient Permeation Enhancer (TPE) technology, which utilizes the medium-chain fatty acid (MCFA) sodium caprylate (C8) to augment the absorption of the somatostatin analog octreotide. At Quotient Sciences, over the last decade, we’ve worked on over 14 oral peptide programs and tested about a dozen different permeation enhancer combinations with them. Permeation enhancers tend to be required in large amounts in formulations, and many of them are usually waxy materials with poor flow, so the tablet formulation and manufacturing process require extra attention and careful design. From an analytics perspective, a lot of the standard quality control tests for tablets have been designed for small-molecule drugs and are yet to be optimized for use with peptides. 🔑HIGHLIGHTS// permeation enhancers as the most advanced and validated technology to overcome bioavailability issues/ worked on over 14 oral peptide programs/ tested about a dozen different permeation enhancer combinations How does Quotient Sciences handle the transition from pre-clinical to clinical development? We’ve pioneered an integrated approach through our Translational Pharmaceutics platform for drug development. This platform combines drug product manufacturing with clinical testing in healthy volunteers, allowing us to be incredibly adaptive in our phase I trial design. Through a tight integration of services, we can manufacture a drug, dose it in healthy volunteers, perform bioanalysis and pharmacokinetic analysis, and use data in real time to inform our next steps. In oral peptide programs, we’ve performed numerous studies where we’ve used this capability to optimize the formulation in response to the clinical data. Typical variables we’ve evaluated are the dose of the peptide and the levels of a permeation enhancer, allowing us to identify the relationship between them to maximize human bioavailability. Through our ability to see the full spectrum of data – from preclinical to clinical – for 11 different peptides and 10 different permeation enhancers, we have built up considerable expertise in the development of oral peptide drug products. This allows us to provide a more streamlined drug development process for our clients, as common challenges across programs can be readily overcome. 🔑HIGHLIGHTS// Translational Pharmaceutics platform for drug development/ combine drug product manufacturing with clinical testing in healthy volunteers/ use data in real time to inform next steps/ 11 different peptides and 10 different permeation enhancers What innovations do you see ahead for oral peptide delivery? I see a real convergence in advances in peptide drug discovery and engineering, together with advances in drug delivery that are really pushing the field forward. Technologies such as phage display mean that vast libraries of peptides can be screened for properties of interest. These are being applied to design peptides specifically for oral delivery. From a drug delivery perspective, approaches such as ingestible devices, ionic liquids and various technologies to exploit active uptake mechanisms are showing real promise. One challenge with oral peptide delivery technologies is that their effectiveness can be significantly impacted by food intake. However, I expect that in the coming years, new methods will be developed to mitigate these food-related effects. I also expect artificial intelligence (AI) to greatly benefit oral peptide delivery. In 2021, the US Food and Drug Administration reported it saw more than 100 drug and biologic application submissions containing elements of AI or machine learning (ML) used in the development process. So three to four years later, that number has likely only increased. All these developments promise to make oral peptide therapies more effective and convenient for patients in the years to come. 🔑HIGHLIGHTS// phage display to screen vast libraries of peptides for properties of interest/ ingestible devices, ionic liquids and various technologies to exploit active uptake mechanisms/ AI will greatly benefit oral peptide delivery To learn more about this topic, watch Quotient Sciences’ latest webinar featuring Dr. Andrew Lewis and Dr. Stuart Mair, Chief Medical Officer at Quotient Sciences. Watch it here.

    Impressions: 1098

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-have-built-considerable-expertise-in-glp-1-drug-development-through-our-oral-peptide-programs

    #SpeakPharma With Quotient Sciences
    14 Oct 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains

    Over the last few decades, the United States and Europe have saved trillions of dollars by importing drugs from countries like China and India. Their journey wasn’t easy, with regulatory non-compliance and drug patent scams raising their ugly heads every now and then. The Covid-19 pandemic and the accompanying lockdowns were a wake-up call for these countries to take a long, hard look at their sourcing strategies.Over the last few years, both the US and Europe have embarked on policy changes and ambitious programs to strengthen their drug supply chains. PharmaCompass takes you through US and Europe’s journeys towards more robust pharmaceutical supply chains.Biden’s executive order, CARES Act, state-backed investments strengthen US supply chainDuring the early days of the pandemic, the US government (under former President Donald Trump)  had enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to address the economic fallout of the pandemic through a US$ 2.2 trillion stimulus. Through this act, the FDA had taken several drug shortage mitigation efforts. The new administration under President Joe Biden undertook more measures. Notable amongst them was Executive Order 14017 on America’s supply chains. It mandated a comprehensive 100-day review to identify vulnerabilities in key sectors, including pharmaceuticals and active pharmaceutical ingredients (APIs). The review noted that 87 percent of generic API facilities are located overseas, leaving the US healthcare system vulnerable to shortages of essential medicines.Through a Presidential Determination, Biden had also broadened US Department of Health and Human Services’ (HHS) authorities under the Defense Production Act (DPA) of 1950. HHS can now enable investment in domestic manufacturing of essential medicines and medical countermeasures under the DPA. The HHS has invested US$ 17 billion in domestic manufacturing for the medical supply chain, including US$ 500 million to support API manufacturing.Under this effort, Merck has been awarded a €121 million (US$ 132 million) government contract to set up a lateral flow membrane production facility at Sheboygan, Wisconsin. Similarly, California has launched an initiative (known as CalRx) and is working with CIVICA to make US$ 30 insulin available to all who need it.Europe encourages reshoring; EDQM develops monographs for unlicensed alternativesIn recent years, Europe has faced shortages of insulin, antibiotics, oncology drugs, corticosteroids and even paracetamol. To overcome these shortages, the European Medicines Agency (EMA) is encouraging drugmakers to enhance manufacturing capacity and diversify suppliers.There is change visible on the ground. Companies like Midas Pharma, EUROAPI, Seqens are setting up API plants in Europe. Seqens has taken steps to reshore paracetamol production in France and is constructing a new € 100 million (US$ 109 million) production unit in Roussillon. Sanofi is investing €1.3 billion (US$ 1.4 billion) in a new insulin production facility at its existing site in Frankfurt. Similarly, Sandoz has set up a new antibiotic production plant in Austria and a new biosimilar development center in Germany.That said, we know that manufacturing capacities take time to build and are often financially unviable in the developed world. Ergo, a particularly innovative initiative has come from the European Directorate for the Quality of Medicines & HealthCare (EDQM). Their project aims to develop monographs detailing the preparation and testing of unlicensed drugs that can fill the gap left when licensed medicinal products are unavailable. To facilitate this initiative, the European Pharmacopoeia Commission is recruiting experts to verify proposed production methods and analytical procedures.The other means of guarding against supply and demand fluctuations is stockpiling. The EMA has advised the European Commission (EC) and marketing authorization holders (MAH) to stockpile medicines. The regulator has also asked MAHs to establish a shortage prevention plan for critical medicines. Europe’s Health Emergency Response Authority (HERA) is taking a systematic approach to stockpile management.Despite these measures, costs and market structures pose serious challenges. Medicines for Europe, representing the generic and biosimilar medicines industry, has raised concerns about the current market structures. They argue that government purchasing practices, which prioritize obtaining the lowest prices for off-patent medicines, are jeopardizing the European manufacturing footprint and discouraging investments in supply chain resilience.FDA, EMA promote continuous manufacturing; US relies on digital stockpilesDuring the pandemic, there were acute shortages of oncology, cardiovascular, anesthesia, anti-infective, neurological and anti-allergic drugs in the US. A 2022 study undertaken by the Washington University points out that there is excess manufacturing capacity in the US that can be considered for reshoring critical and essential drugs. In fact, 49 percent of generic drug manufacturing capacity in the US is lying idle, and many others are working at less than 50 percent capacity. These capacities can be repurposed. Various advanced manufacturing technologies, such as  “continuous flow and on-demand manufacturing capabilities in idled manufacturing sites offer the ability to reduce production cost,” says this report.FDA has been promoting “advanced manufacturing” technologies, such as continuous manufacturing, which are now a part of America’s overall strategy to strengthen and secure the pharmaceutical supply chain. The EMA has also released guidelines on continuous manufacturing of drug substances and drug products. Advanced manufacturing is a collective term for new or innovative medical product manufacturing technologies. Unlike batch manufacturing, which involves sequential processing and testing of material across multiple discrete stages (and often discrete facilities), continuous manufacturing combines the full manufacturing stream into a single, fully integrated flow. While continuous manufacturing may not be suitable for every drug manufacturing process, but where applicable, it tends to eliminate built-in production gaps and shortens the time taken to manufacture a drug from months to days.In the US, the Strategic National Stockpile (SNS) plays a critical role in ensuring the availability of essential medical supplies during emergencies. It now also involves a digital stockpile that does not store physical goods and products. Instead, it stores electronic plans, instructions, and methods to make and test medical products. Digital stockpiles rely on one or more trusted suppliers that can make the product from the digital information, either through methods like 3D printing or self-contained distributed manufacturing lines.Our viewThe global pharmaceutical supply chain is a complex web spanning multiple countries and continents. While advanced manufacturing and stockpiling may work to an extent, a large chunk of generic drugs and APIs will continue to come from countries like China and India.In order to reduce reliance on China, the US has been proactively expanding its collaboration with India. But this time, there is increased emphasis on quality control. While FDA is increasing the number of inspections at Indian drug plants, the Indian government, on its part, has revised rules for drug manufacturing, with higher GMP standards.Taken together, a multi-pronged approach to addressing supply chain vulnerabilities should secure drug supplies to the US and Europe in the years to come.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 472

    https://www.pharmacompass.com/radio-compass-blog/us-europe-turn-to-advanced-manufacturing-stockpiling-to-strengthen-drug-supply-chains

    #Phispers by PHARMACOMPASS
    17 Oct 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Lonza Completes Acquisition of Biologics Site from Roche
    Lonza Completes Acquisition of Biologics Site from Roche

    01 Oct 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-10-01/lonza-completes-acquisition-of-biologics-site-from-roche/?widget=listSection

    CONTRACT PHARMA
    01 Oct 2024
    Share Share
    Acumen Pharma Extends Alzheimer’s Collaboration with Lonza
    Acumen Pharma Extends Alzheimer’s Collaboration with Lonza

    27 Sep 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-09-27/acumen-pharmaceuticals-extends-alzheimers-collaboration-with-lonza/?widget=listSection

    CONTRACT PHARMA
    27 Sep 2024
    Share Share
    Vertex adds CDMO Lonza to Casgevy production network
    Vertex adds CDMO Lonza to Casgevy production network

    24 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/vertex-taps-lonza-help-produce-global-supply-cutting-edge-crispr-therapy-casgevy

    FIERCE PHARMA
    24 Sep 2024
    Share Share
    Lonza Launches Innovaform Accelerator CoE in France
    Lonza Launches Innovaform Accelerator CoE in France

    19 Sep 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-09-19/lonza-launches-innovaform-accelerator-coe-in-france/?widget=listSection

    CONTRACT PHARMA
    19 Sep 2024
    Share Share
    Lonza Completes Microbial Manufacturing Expansion in Visp
    Lonza Completes Microbial Manufacturing Expansion in Visp

    05 Sep 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-09-05/lonza-completes-microbial-manufacturing-expansion-in-visp/?widget=listSection

    CONTRACT PHARMA
    05 Sep 2024
    Share Share
    Lonza Upgrades Clinical Manufacturing Services at Bend Site
    Lonza Upgrades Clinical Manufacturing Services at Bend Site

    07 Aug 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-08-07/lonza-upgrades-clinical-manufacturing-services-at-bend-site/?widget=listSection

    CONTRACT PHARMA
    07 Aug 2024
    Share Share

    Services

    Upload your portfolio for free, ask us

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Lonza Group and get a quotation

    Lonza Group is a supplier offers 74 products (APIs, Excipients or Intermediates).

    Find a price of Niacin bulk with CEP, JDMF offered by Lonza Group

    Find a price of Nicotinamide bulk with CEP, JDMF offered by Lonza Group

    Find a price of Nicotinamide bulk with DMF, JDMF offered by Lonza Group

    Find a price of Desmopressin Acetate bulk with CEP offered by Lonza Group

    Find a price of Niacin bulk with CEP offered by Lonza Group

    Find a price of Bovine Serum bulk with CEP offered by Lonza Group

    Find a price of Fluvoxamine bulk with DMF offered by Lonza Group

    Find a price of Sirolimus bulk with DMF offered by Lonza Group

    Find a price of Voclosporin bulk with DMF offered by Lonza Group

    Find a price of MC-VAL-ALA-PBD bulk with DMF offered by Lonza Group

    Find a price of EC-125 DRUG SUBSTANCE bulk with DMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO feed base A bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-CHO7 Liposome Solution bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-ProCHO5 bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-Power Feed A Power Kit (Power Feed A (without lipids)) bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives ・ X-VIVO 15 Medium with transferrin without phenol red or gentamicin bulk with JDMF offered by Lonza Group

    Find a price of Cell · Lonza Walkersville bone marrow stem cells bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO vitamin mixture bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO feed-based E bulk with JDMF offered by Lonza Group

    Find a price of Medium / media supplements · Lonza Walkersville PowerCHO2-C D bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-Lonza Walkersville X-VIVO 15 bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-Power CHO-2 Powerer Kit (Power CHO-2 Medium) bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives ProPER-1 basal powerer w / 6g / L Gluc & 6 mM L-Gln bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-PowerCHO-2 CD_Verviers bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · Lonza Walkersville ProCHO-5 bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive supplement E bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO feed base D bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-PowerCHO-2 bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · Lonza Verviers X-VIVO 15 bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-CHO7 Lipids bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additive / CHO Feed Base B bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO trace element solution bulk with JDMF offered by Lonza Group

    Find a price of Medium / Medium Additives-PowerCHO-2_Verviers bulk with JDMF offered by Lonza Group

    Find a price of Medium / medium additive · CHO feed-based F bulk with JDMF offered by Lonza Group

    Find a price of 1-Mercaptomethyl-Cyclopropyl-Acetic Acid bulk offered by Lonza Group

    Find a price of 7-Hydroxystaurosporine bulk offered by Lonza Group

    Find a price of Alimemazine bulk offered by Lonza Group

    Find a price of Auranofin bulk offered by Lonza Group

    Find a price of Bovine Serum bulk offered by Lonza Group

    Find a price of Bromfenac Sodium bulk offered by Lonza Group

    Find a price of Desmopressin Acetate bulk offered by Lonza Group

    Find a price of Eflornithine Hydrochloride bulk offered by Lonza Group

    Find a price of Eprosartan bulk offered by Lonza Group

    Find a price of Eprosartan Mesylate bulk offered by Lonza Group

    Find a price of Etodolac bulk offered by Lonza Group

    Find a price of Ketosulfone bulk offered by Lonza Group

    Find a price of L-Carnitine Tartrate bulk offered by Lonza Group

    Find a price of Levocarnitine bulk offered by Lonza Group

    Find a price of Luteolin bulk offered by Lonza Group

    Find a price of Motexafin Gadolinium bulk offered by Lonza Group

    Find a price of Niacin bulk offered by Lonza Group

    Find a price of P-Hydroxyamphetamine bulk offered by Lonza Group

    Find a price of Phenoxybenzamine HCl bulk offered by Lonza Group

    Find a price of Prochlorperazine Edisylate bulk offered by Lonza Group

    Find a price of Propylhexedrine bulk offered by Lonza Group

    Find a price of Thymidine bulk offered by Lonza Group

    Find a price of Trabectedin bulk offered by Lonza Group

    Find a price of Tranylcypromine Sulfate bulk offered by Lonza Group

    Find a price of Triamterene bulk offered by Lonza Group

    Find a price of Voclosporin bulk offered by Lonza Group

    Find a price of EC-037 bulk offered by Lonza Group

    Find a price of D5AA bulk offered by Lonza Group

    Find a price of TP4 bulk offered by Lonza Group

    Find a price of SB 217063 AND SK&F 109077 bulk offered by Lonza Group

    Find a price of DEBMEB bulk offered by Lonza Group

    Find a price of BULK PURIFIED HUMAN MONOCLONAL ANTIBODY (ANTI-IL8) (NSO CELLS, LONZA) TO IL-8 bulk offered by Lonza Group

    Find a price of CN 343 (SAS) bulk offered by Lonza Group

    Find a price of 2-BUTYL-3-H-IMIDAZOL-4-CARBALDEHYDE (IMALOC SB 202783) bulk offered by Lonza Group

    Find a price of TERT-BUTYL (S)-3-(TERT-BUTYLCARBAMOYL) PIPERAZINE-1-CARBOXYLATE bulk offered by Lonza Group

    Find a price of CRUDE SG-3249 bulk offered by Lonza Group

    Find a price of SECAMINE HYDROCHLORIDE bulk offered by Lonza Group

    Find a price of SB 200473 bulk offered by Lonza Group

    Find a price of SB 201999 bulk offered by Lonza Group

    Find a price of FACILITY AND OPERATING PROCEDURES IN VISP, SWITZERLAND bulk offered by Lonza Group

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search